<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: There has been continuous debate as to whether Y chromosome loss is an age related phenomenon or a cytogenetic marker indicating a malignant change </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to investigate the frequency of Y chromosome loss in the specific patients in order to determine whether it is an age related phenomena or a cytogenetic marker indicating a malignant change </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Five hundred and ninety-two male patients with a median age of 59 years old (22 - 95 years) were included in this study </plain></SENT>
<SENT sid="3" pm="."><plain>These patients were divided into two groups: the study group, including 237 patients who had <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> included <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM), and <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and the control group including 355 patients with no evidence of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Both conventional cytogenetics and fluorescence in situ hybridization using DNA probes specific for the centromere of chromosomes X or Y were performed according to our standard laboratory protocols </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Twenty-four out of 237 patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> (10.1%) had Y chromosome loss </plain></SENT>
<SENT sid="6" pm="."><plain>Of these 24 patients, 2 patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (5.0% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients), 2 patients had <z:mp ids='MP_0005481'>CML</z:mp> (5.7% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0005481'>CML</z:mp> patients), 2 patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> (8.0% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> patients), 3 patients had MM (10.0% of <z:hpo ids='HP_0000001'>all</z:hpo> MM patients), 5 patients had <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (10.6% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients) and 10 patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (16.7% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients) </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty-one out of these 24 patients had a loss of Y chromosome as the sole anomaly and the remaining three had a loss of Y chromosome accompanied with other structural changes detected by conventional cytogenetic analysis </plain></SENT>
<SENT sid="8" pm="."><plain>Fluorescence in situ hybridization (FISH) analysis confirmed the routine cytogenetic results </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 24 patients had a loss of Y chromosome with a range of 17.5% - 98.5% of cells </plain></SENT>
<SENT sid="10" pm="."><plain>Two of the patients, one with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and another with <z:mp ids='MP_0005481'>CML</z:mp>, had karyotype and FISH testing done both at the initial diagnosis and during remission </plain></SENT>
<SENT sid="11" pm="."><plain>The results showed a loss of Y chromosome at initial diagnosis but a <z:mpath ids='MPATH_458'>normal</z:mpath> 46, XY karyotype during remission </plain></SENT>
<SENT sid="12" pm="."><plain>Only 9 out of 355 patients (2.5%) without evidence of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e> had Y chromosome loss, among them 7 patients had <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> and 2 patients had <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney diseases</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Comparison of the incidence of Y chromosome loss in patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> or without evidence of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disease</z:e> using statistical analysis showed a statistically significance difference (P &lt; 0.05) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: The present study demonstrated that the frequency of Y chromosome loss is significantly higher in patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> than in patients without <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e>, which indicates that the loss of Y chromosome is associated with a neoplastic change </plain></SENT>
</text></document>